a business development look at the cns landscape
TRANSCRIPT
PULLAN’S PIECES, PART IIA BUSINESS DEVELOPMENT LOOK AT THE CNS LANDSCAPE
By Linda M. Pullan, PhD, Pullan Consulting
The unmet needs in CNS are huge. With one hundred million Americans affected by neurological disorders and 43 million Americans suffering
from some type of mental illness, the societal impact of CNS afflictions is astronomical. There may be no other therapeutic area where
the unmet needs are bigger. What’s more, these diseases are often accompanied by a “loss of self,” which in itself is devastating.
100MAmericans affected by neurological disorders (MID Report 2018)
43.4MAmerican adults have a mental illness(MID Report 2017)
&
ShareVault and Pullan Consulting
2
The numbers of indications with drugs in development are also impressive, both in the categories of neurology and psychiatry.
Indications shown in orange have over 7 million patients.
Chronic Neurological
• Alzheimer’s• Chronic
Inflammatory Demyelinating Polyneuropathy
• Complex Regional Pain Syndrome
• Dyskinesia• Epilepsy• Fibromyalgia• HD• MCI• Migraine• MS• Multi-focal Motor
Neuropathy• Neuropathic
Pain• NMO• PD• Trigeminal
Neuralgia
Acute and Semi-Acute
• Cancer pain• Cataplexy• Guollain-Barré• Headaches• Pain• Stroke• TBI
Orphan Neurology
• ALS• Ataxias• Batten Disease• Broca Aphasia• Canavan Disease• Carnosinemia• Cerebral Palsy• Dravet
Syndrome• Friedreich Ataxia• Globoid Cell
Leukodystrophy• Syringomyelia• Tardive
Dyskinesia• Hyperkalemic
Periodic Paralysis
• Kluver-Bucy Syndrome
• Lennox Gastaut• Meige’s
Syndrome• Metachromatic
Leukodystrophy• Pick Disease• Rett Syndrome• Schindler
Disease• Simian B Virus
Infection• SMA
Neu
rology • ADHD
• Alcohol addiction
• Anorexia Nervosa
• Autism• Binge eating• Bipolar
Disorder• Dementia• Depression• Insomnia• Narcolepsy• Panic Disorder• PTSD• Schizophrenia• Tourette
Syndrome
Psychiatry
A Business Development Look at the CNS Landscape
3
HOW DOES THE CNS LANDSCAPE COMPARE TO THAT OF CANCER?
Compared to cancer, there are more companies focused on CNS, but there are fewer drugs in Phase I, II, and III. Presumably, this means that many of the CNS companies are young and work in the preclinical and discovery phases.
Sales in CNS Are Big, But Smaller Than Cancer
Sales in CNS represent about 7.5% of all pharmaceutical sales. A majority of the sales (55%) are in the US, which is a larger percentage compared to the percentage of sales in the US for the pharmaceutical industry as a whole, which is about 40%.
2018: Top 10 Drug Sales
The magnitude of sales in CNS is significant. To make the top ten list, sales must be over $1.7 billion. From this chart, we can see that there is a heavy emphasis on multiple sclerosis. Also, there are a few peptides and proteins (yellow bars)and an antibody (red bar), but most drugs being marketed for CNS are small molecules. Interestingly, most of the molecules are the result of a licensing deal, partnership, or
$0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000
Lyrica (Pfizer, VDCa Channel, small mol., 2004)
Tecfidera (Biogen, NFE2L2, small mol., 2013)
Botox (Allergan,SNAP25 , protein, 1991)
Gilenya (Novartis, S1PR1, small mol., 2010)
Invega Sustenna (J&J, amine R, small mol., 2009)
Vyvanse (Takeda, monoamine transport, small mol. 2007)
Ocrevus (Roche,CD20, Ab, 2017)
Copaxone (Teva, MHC Class II, peptide, 1996)
Aubagio (Sanofi, DHODH, small mol., 2012)
Avonex (Biogen, IFNAR1, protein, 1996)Dru
g (C
o, T
arg
et, M
ol. T
ype,
1st
ap
pro
val)
2018 sales, millions
From Northwestern U
From Fumapharm AG
From Mitsubishi Tanabe
From Shire
From Biogen/Genentech
From Weizmann Institute
From Aventis
MS
MS
Pain
MS
MS
MS
MS
Aesthetics+
Schizophrenia
ADHD
0
2000
4000
6000
8000
10000
Drugs in Phase 1,2, 3 Companies
CNS vs cancer# drugs, # companies
CNS Cancer
$-
$20
$40
$60
$80
$100
$120
$140
CNS cancer
2018 Sales $B
ShareVault and Pullan Consulting
4
M&A deal. This highlights the tremendous reliance of the pharmaceutical industry on dealmaking and alliances.
Also of note are the first approval dates, some of which are quite old, with first approvals in 1991 and 1996. Yet these early approved drugs are still leading in sales, indicating that it’s possible to build very large sales in CNS and hold on to them for many years.
2018: Top 10 Companies
Again, we see from this chart that sales in CNS are significant. To make the top 10 list of companies, sales must be at least $2.6 billion. Biogen leads the industry with over $10 billion in sales.
WHAT’S IN THE PIPELINE?
Biogen, $10,319
Pfizer, $7,992
Allergan, $4,826J&J, $4,328
Novartis, $3,786
Sanofi, $3,224
Shire, $2,799
Roche, $2,754
Otsuka, $2,699
UCB, $2,652 2018 CNS Sales, $M
0 5 10 15 20 25 30 35
BiogenPfizer
AllerganJ&J
NovartisSanofi
Takeda/ShireRoche
OtsukaUCB
# Drugs in CNS Pipelines of Top 10 Companies Based on 2018 CNS Sales
phase 1 phase 2 phase 3 pre-registration
A Business Development Look at the CNS Landscape
5
When looking at clinical development pipelines, we see that Biogen, Pfizer and Roche have pretty healthy pipelines. UCB, Otsuka and Sanofi, have leaner pipelines. With attrition rates what they are, it takes a lot of molecules to maintain healthy sales. Based on this data, it may be challenging for most of these companies to keep their top-10 slot.
Interestingly, most pipeline drugs are not being developed by the top 10 companies. This chart shows that there are a great deal of drugs in small companies and those with no revenue. This situation presents many potential opportunities for partnering.
PROBABILITY OF SUCCESS BY STAGE
When looking at success rates by stage, it’s apparent that CNS is a tough segment of drug development. The likelihood of approval of all therapeutic areas combined is above 17%, but all CNS categories are much lower.
Phase 1 Phase 2 Phase 3Registration to Approval
Overall LOA
Neurology/CNS 63.6% 36.2% 54.8% 85.1% 10.7%
Psychiatry 57.0% 23.5% 59.5% 84.8% 6.7%
CNS Orphan 85.0% 56.3% 32.0% 5.0%
All Therapeutic Areas 70.6% 47% 61.8% 84.6% 17.3%
https://www.alacrita.com/whitepapers/pharmaceutical-probability-of-success
020406080
100120140160
>=$25Brevenue
$5 to <$25B $1B to <$5 $0.1B to <$1B $1M to $99M 0 to $0.99M
CNS Drugs in Phase 1-3 by Company Revenues
companies drugs in Phase 1,2,3
ShareVault and Pullan Consulting
6
TOP CNS INDICATIONS IN PHASE II
If indications in Phase II are indicative of what’s to come, we see that most of the solutions are focused on neurology, not psychiatric disorders. Despite the unmet need, not a lot of psychiatric drugs are being developed. Pain is a significant focus, as are neurodegenerative diseases, Parkinson’s, Alzheimer’s and cognitive disorders.
ROUTES OF ADMINISTRATION
The routes of administration of Phase II CNS drugs are impressively varied. Oral is the dominant category, with intravenous and subcutaneous second and third. But observe the numerous specialized routes, such as intrathecal, intracerebral, as well as intramuscular, inhalation, and ophthalmic. There are remarkable diverse routes of administration being employed.
50 100 150 200 250 300
NeurologyPain
Psychiatric DisordersNeurodegenerative Diseases
Movement DisordersAlzheimer's DiseaseParkinson's DiseaseCognitive Disorders
Neuropathic Pain (Neuralgia)Mixed Pain (Nociceptive Pain/Neuropathic Pain)
Top indications in Phase 2, # of Drugs
buccal or sublingual, 12epidural, 4
inhalation, 27
intraarticular, 37
intracerebral, 15
intradermal, 15
intramuscular, 40
intrathecal, 33
intravenous, 345
nasal, 30
ophthalmic, 15oral, 756
parenteral, 33subcutaneous,
180
topical or cutaneous, 58
Routes of Phase 2 CNS Drugs, # drugs
A Business Development Look at the CNS Landscape
7
TARGET CLASSES
The target classes are perhaps less varied than one would expect. Receptors, enzymes, and ion channels dominate. Transporters have historically been a big category, but it’s a relatively small chunk in Phase II. Amyloid and tau are still a significant chunk. Cytokines, membrane proteins, and nerve proteins make up the rest.
DESIGNATIONS FOR CNS PHASE II DRUGS
Orphan drugs comprise about 20% of Phase II CNS drugs (100 out of 474). Breakthrough designations are fairly rare, and 505b2, where the data from an existing drug is used to substantiate a new formulation of that drug, makes up a significant portion. Combinations are also a significant portion, but much less so than in oncology. Finally, extended or sustained release drugs comprise a surprisingly small piece of CNS designations.
BIOMARKERS
The use of biomarkers in CNS Phase III trials is rarer than in cancer.
The patient selection and stratification biomarkers are particularly small in CNS trials. Some of this has to do with access to materials, as there are probably very
Target Classes in Phase 2 CNS Drugs
receptor
enzyme
ion channels
transporter
other
amyloid
tau and cytoskeleton
growth factor
cytokines
membrane protein
nerve protein (ataxin, synuclein)
0 20 40 60 80 100 120
Extended or sustained release
Combination
505b2
breakthru
Orphan
Designations for CNS Phase 2 drugs (474 total)
ShareVault and Pullan Consulting
8
few brain biopsies to be utilized for brain biomarkers. Still, it’s surprising how few biomarkers are being used in CNS Phase III trials.
2025 SALES FORECAST
Sales for the top 10 molecules in 2025 is quite a different list than what we saw for 2018. Most of the molecules that were on the 2018 list are not in the 2025 forecast. However, Botox, Ocrevus (the Roche CD20 antibody), Invega, and Biogen’s MS drug, Tecfidera, will still be on the list.
$0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 $8,000
Ocrevus (Roche,CD20, Ab, 2017)
Botox (Allergan,SNAP25 , protein, 1991)
Invega Sustenna (J&J, amine receptor, small mol., 2009)
Tecfidera (Biogen, NFE2L2, small mol., 2013)
Spinraza (Biogen, SMN2, antisense, 2016)
SAGE-217 (Sage Therapeutics, GABAR, small mol, Phase III)
Rexulti (Otuska, multi DA 5HT R, small mol, 2015)
Epidiolex (GW, CB1/CB2/GPR55/TRPV, small mol, 2018)
Spravato (J&J, NMDAR, small mol, 2019)
Zolgensma (Novartis, SMN2, AAV gene, 2019)
2025 Sales ForecastDrug (Co, Target, Molecule Type, First Approval)
From Cold Spring Harbor Lab
From Nationwide Children’s Hospital, OSU, AveXis
MS
MS
Depression
Depression
SMA
SMA
Depression
Seizures
Aesthetics+
Schizophrenia
1646
1305
4903
Biomarkers in Cancer Phase 3 trials
efficacypatient selection/stratificationno biomarker
657145
7260
Biomarkers in Phase 3 CNS trials
efficacy biomarkerspatient selection/stratificationno biomarker
A Business Development Look at the CNS Landscape
9
Not all the top sellers are small molecules, with antisense, gene therapy new entrants. The other big shift is that depression and seizures appear, and the list is no longer dominated by MS. The other phenomenon is that fewer of the molecules will come in via deals, which indicates that some smaller companies will be working hard to develop their own molecules and are expected to do very well.
2025 TOP 10 COMPANIES
When looking at the top 10 companies in expected sales for 2025, we will see some of the same players, such as Biogen, which tops the list. But other companies, such as Lundbeck, Teva, Merck and Lily, are coming into play in 2025 and expected to be substantially bigger in CNS sales than they are today.
GLOBAL SALES OF LEADING SCHIZOPHRENIA DRUGS
Looking at the indication of schizophrenia, this chart demonstrates the impact on sales of patent expirations. For example, when Abilify went generic in 2014, sales dropped drastically.
Though some drugs are forecast to have an increase in sales, these increases will not reach the levels of the large sales in the past for schizophrenia. Because the generic price pressures will be so substantial, the new drugs will not achieve the sales that were realized in the past. Despite the huge unmet needs, without new mechanisms, large sales are not forecast for schizophrenia.
$0
$1,000
$2,000
$3,000
$4,000
$5,000
$6,000
$7,000
$8,000
$9,000
2011 2012 2013 2014 2015 2016 2017 2018 2019(F) 2020(F) 2021(F) 2022(F) 2023(F) 2024(F) 2025(F)
Leading Schizophrenia Drugs Global Sales
Invega Sustenna (J&J, 2009-2019) Rexulti (Otsuka and Lundbeck, 2015-2026)Abilify Maintena (Otsuka and Lundbeck, 2013-2024) Vraylar (Allergan, 2015-2027)Latuda (Sumitomo Dainippon, 2010-2026) Zyprexa (Lilly, 1992-2001)Abilify (BMS and Otsuka, 2002-2014) Vraylar (MTPC, 2015-2027)Seroquel XR (AstraZeneca, 2007-2009)
Invega Sustenna
Abilify
Abilify MaintenaRexulti
Latuda
Zyprexa
Vraylar
Seroquel XR
ShareVault and Pullan Consulting
10
MECHANISMS
One reason that this segment will not have sufficient sales to make up for losses due to patent expirations is that there are few new mechanisms. We’re seeing the same mechanisms that have been used for a long time, such as dopaminergic and other neural transmitter signaling. Since they are not novel, it’s hard to achieve blockbuster sales in the face of patent expirations on the old schizophrenia drugs.
SCHIZOPHRENIA’S UNMET NEEDS
There are still many unmet medical needs in schizophrenia. The existing drugs are predominantly effective on the positive symptoms, such as acting out, but also result in a dampening of effect. They don’t address the negative symptoms and other side effects that patients complain about, such as cognitive impairment. Often this results in problems with patient compliance, and it highlighting the urgent need for new approaches to treat schizophrenia.
MS SALES FORECASTS
Source: GlobalData, Proprietary Marketed Products Database
$0
$500
$1,000
$1,500
$2,000
$2,500
$3,000
$3,500
$4,000
$4,500
2019(F) 2020(F) 2021(F) 2022(F) 2023(F) 2024(F) 2025(F)
MS Sales Forecasts
Tecfidera (Biogen, 2013, 2020) NFE2L2 oral
Tysabri (Biogen, 2004, 2020) Integrin A4
Mayzent (Novartis, 2019, 2024) SIPR oral
Arzerra (Novartis, 2020?, 2023) CD20
Avonex (Biogen, 1996, 2007) interferon
Vumerity (Biogen, 2020?, 2030) NFE2L2 oral
Gilenya (Novartis, 2010, 2019) S1PR oral
Plegridy (Biogen, 2014, 2025) peg interferon
Copaxone (Teva, 1996, 2014) MHC
A Business Development Look at the CNS Landscape
11
In 2018, MS was the dominant indication for the top 10 drugs. Seven years later, MS is not nearly as dominant in the top 10 drugs. Again, future patent expirations and the generic price pressures will really impact MS drug sales. We have yet to see the next wave of therapeutics that differ sufficiently from the targeted immunosuppressants to make an impact in sales.
SMA SALES FORECASTS
In SMA, we see a rapid rise in sales for first entrants. This is a classic example of the power of being the first to enter a new market space. With SMA, there have been six entrants into a disease that previously had no effective treatments. We therefore see a rapid increase in sales in the early years and then a gradual slowing.
ALZHEIMER’S SALES FORECASTS
Alzheimer’s has proven to be a very tough therapeutic area. Aricept was approved in 1996, and the patent expired in 2006. This acetylcholinesterase inhibitor has hung in there for a long, long time. It has benefits for some patients, but certainly can’t be said to be a significant cure.
500
1,000
1,500
2,000
2,500
2016 2017 2018 2019(F) 2020(F) 2021(F) 2022(F) 2023(F) 2024(F) 2025(F)
Sale
s, $
mill
ions
Leading Drugs in SMADrug (Co., 1st approval, expiry)
Spinraza (Biogen, 2016-2025) antisense SMN
Zolgemsa (Novartis, 2019-2031) gene Tx SMN
Risdiplam (Roche, ?-2029) small mol SMN
Reldesemtiv (Astellas, ?-2032) troponin small mol
Reldesemtiv (Cytokinetics, ?-2032) troponin small mol
Branaplam (Novartis, ?-2031) small mol SMN
SpinrazaZolgemsa
Risdiplam
$0
$200
$400
$600
$800
$1,000
$1,200
$1,400
2019(F) 2020(F) 2021(F) 2022(F) 2023(F) 2024(F) 2025(F)
Sales Forecasts in Alzheimer's
vafidemstat (Oryzon, 2024, 2034) MAO-B, LSD1
Solanezumab (Lilly, 2020?, 2032) Amyloid
Bryostatin-1 (Neurotrope, 2022, 2033) PKCepsilon
Azeliragon (vTV, 2025, 2033) AGER
Aricept (Eisai, 1996, 2006) AChE
Donanemab (Lilly, 2021, 2033) amyloid
Elenbecestat (Eisai, 2022?, 2031) beta secretase
Dexmedetomidine (BioXcel, 2021?, 2031) ADRA2
ShareVault and Pullan Consulting
12
Alzheimer’s sales remain fairly stagnant and analyst forecasts are generally not optimistic. The one drug showing substantial sales in the 2025 time frame is an epigenetics and MAOB approach. This is a disease with a huge unmet need, and there isn’t much on the horizon that has the potential to be a blockbuster. Again, we need new approaches.
2019 DRUG DEVELOPMENT PIPELINE
PARKINSON’S SALES FORECASTS
Sympt
om-R
educ
ing
Smal
l Mol
ecul
e
Source: Cummings, J et al, Translational Research and Clinical Interventions 5:272 (2019)
$0
$200
$400
$600
$800
$1,000
$1,200
2019(F) 2020(F) 2021(F) 2022(F) 2023(F) 2024(F) 2025(F)
Parkinson's Sales Forecasts
AXO-Lenti-PD (Axovant, 2022?, 2034) gene tx
Inbrija (Accorda, 2018, 2032) levodopa inhaled
Accordion Pill (Intec, 2021?, 2031) levodopa, carbidopa
VYAADC-01 (Voyager, 2023?, 2034) gene tx
Ongentys (Neurocrine, 2020?, 2026) COMT
(Carbidopa + Levodopa) (MTPC, 2021? 2029)
Blarcamesine (Anavex, 2021?, 2029) NMDAR
A Business Development Look at the CNS Landscape
13
In Parkinson’s we also see that fairly stagnant growth is expected, but we do see that gene therapy has the potential to be a significant player in the future. Most of the other drugs on this list are well-known mechanisms and combinations, that is, drugs that may see incremental improvement, but are not expected to gain blockbuster status. It’s difficult to get to those blockbuster sales forecasts with things that are only incrementally superior to generics.
DEPRESSION SALES FORECASTS
In depression, most of the serotonergic transport inhibitors have been generic for some time. They continue to have decent sales, but nowhere near the sales of the past. Dollar volume has declined dramatically, but patient volume has not been responsible. A few new approaches may have some impact, such as those employing GABAA, AMPA, and the NMDA receptor. Though Esketamine had generated tremendous hope, so far it hasn’t delivered significant sales, since its benefit of the more rapid effect has the trade-off of side effects.
MIGRAINE SALES FORECASTS
Migraine, much like SMA, is an area where the world has changed. Prior to 2019, we saw the expiration of almost all of the triptans—Sumatriptan, Zomig, Maxalt, and so forth, which had been a huge revolution at their release and represented the dominant sales in migraine. Now the CGRP agonists, mostly antibodies, have been selling well, and some oral CGRP molecules have potential. And there is one 5HT1F molecule in the list from Lilly.
$0
$200
$400
$600
$800
$1,000
$1,200
$1,400
$1,600
$1,800
$2,000
2019(F) 2020(F) 2021(F) 2022(F) 2023(F) 2024(F) 2025(F)
Sales Forecast in Depression
SAGE-217 (Sage, 2021?, 2031) GABA
AV-101 (VistaGen, 2021?, 2031) AMPA
((Bupropion + Dextromethorphan),Axsome, 2021?, 2031) nChR+ NMDA
Viibryd (Allergan, 2011, 2019) 5HTT
Zoloft (Pfizer, 1991, 1999) 5HTT
Effexor (Pfizer, 1997, 2003) 5HTT
ShareVault and Pullan Consulting
14
THE DEALS
This chart, which shows the fraction of deals that are M&A, VC deals, and partnerships, is consistent with other therapeutic areas, in that licensing partnerships are the predominant form of deals and is a much larger share than the number of VC deals or the number of M&A deals.
$0
$200
$400
$600
$800
$1,000
$1,200
$1,400
$1,600
$1,800
2019(F) 2020(F) 2021(F) 2022(F) 2023(F) 2024(F) 2025(F)
Migraine Sales Forecasts
Aimovig (Amgen, 2019, 2031)
Emgality (Lilly, 2018, 2031)
Zydis (Biohaven, 2020?, 2030) oral
Eptinezumab (Alder, 2020?, 2032)
Aimovig (Novartis, 2018, 2031)
lasmiditanm (Lilly, 2019?, 2029) oral 5HT1F
Ubrogepant (Allergan, 2020?, 2030) oral
Atogepant (Allergan, 2022?, 2032) oral
VC deals, 907
Partnerships, 1428
M&A, 619
CNS deals 2014 thru 8/6/2019
0
20
40
60
80
100
120
140
2014 2015 2016 2017 2018 2019
Number of M&A Deals per Year
A Business Development Look at the CNS Landscape
15
CNS M&A DEALS
2019 is shaping up to be a strong year for M&A, but will likely not compete with 2016, when M&A deals in CNS peaked. The number of deals in CNS per year is relatively small, generally between 60 and 100 per year.
MOST ACTIVE COMPANIES IN CNS M&A
This chart shows the top companies that are doing M&A deals in CNS.
NUMBER OF M&A DEALS IN CNS BY COUNTRY
Most CNS acquisitions are for US companies. Note that China is not on this list, which differs from oncology, where China is responsible for a slightly larger number of the M&A deals.
0 1 2 3 4 5 6 7 8 9 10
Abbott
Astellas
Lundbeck
Juno
Novartis
Teva
Mallinckrodt
Merck &Co
Pfizer
Allergan
Number of Deals
Most Active in CNS M&A 2014 to 8/8/2019
0
10
20
30
40
50
60
70
80
United States United Kingdom Canada India Australia Germany
Number of M&A Deals in CNS by Country, 2015 thru 8/8/2019
2015 2016 2017 2018 2019
ShareVault and Pullan Consulting
16
CNS M&A DEALS BY STAGE OF MOST ADVANCED ASSET
Compared to cancer, marketed drugs are more prevalent in M&A deals in CNS, but a significant number of preclinical deals are taking place, along with deals in Phase I, II and III. Most deals take place at Phase II and beyond.
CNS M&A DEALS BY MOLECULE TYPE
Small molecules dominate M&A deals in CNS, but these deals are getting done across a wide variety of types of molecules.
VC DEALS
The number of VC rounds per year in CNS has been generally steady for the last five years, and the number of VC deals and the deal value in 2019 are on track with the previous four years.
Discovery, 4Preclinical, 26
Phase 1, 19
Phase 2, 37Phase 3, 21
Marketed, 64
# CNS M&A deals by stage of most advanced asset
0 20 40 60 80 100 120 140 160
small molecule
protein
peptide
Ab
gene therapy
cell
oligo or antisense
vaccine
polysaccharide
CNS M&A Deal Number by Molecule Type(Note: deals often include more than one type.)
$-
$500
$1,000
$1,500
$2,000
$2,500
$3,000
$3,500
$4,000
$4,500
0
50
100
150
200
250
2015 2016 2017 2018 2019
# ro
unds
CNS VC Rounds by Year
No Of Deals Value (US$m)
A Business Development Look at the CNS Landscape
17
NUMBER OF VC DEALS IN CNS BY COUNTRY
NUMBER AND VALUE OF SERIES A AND B ROUNDS IN CNS
Who’s doing Series A and B round in CNS? This area looks quite different from oncology, a field where a number of corporate venture arms are among the most active in early round deals. Instead, in CNS, the players who have been the most active in series A and B rounds includes only one corporate VC.
LICENSING DEALS
CNS licensing deals have been steady in recent years, both in number and value, and 2019 looks to be no different. Note (on the next page) that there are many more deals here in licensing than in M&A and VC.
0
50
100
150
200
United States UnitedKingdom
France Israel Canada China
#VC deals in CNS by Country
2015 2016 2017 2018 2019
$0
$100
$200
$300
$400
$500
$600
$700
$800
$900
0
2
4
6
8
10
12
14
16
18
ARCH VenturePartners LP
AlexandriaVenture
Investments
OrbimedAdvisors LLC
FidelityManagement &
ResearchCompany
Johnson &Johnson
Innovation -JJDC Inc
CormorantAsset
ManagementLLC
Partner FundManagement
LP
Polaris PartnersLLC
Atlas VentureInc
Dolby FamilyVentures LP
# ro
unds
# and Value of Series A and B rounds in CNS
No.of Deals Value (US$m)
ShareVault and Pullan Consulting
18
CNS LICENSING DEALS BY STAGE
CNS licensing deals are most often done in the preclinical and marketed stages. This is somewhat different than in oncology, where the percentage for marketed drugs is much smaller. The preclinical percentage is similar to oncology, and the Phase II percentage is a bit smaller than in oncology, but the basic message is the same—most deals are done in preclinical, Phase II, and beyond. Phase I is a tougher arena for deals. Phase III is also often a tougher arena because companies need lead time to be ready to launch, and often the best opportunities are perceived to have been picked up in Phase II when there are signs of efficacy, but everything’s still not complete.
COMMON MOLECULE TYPES IN CNS LICENSING
Small molecules own the dominant share of CNS licensing deals, but there are a significant variety of other molecule types, which could reflect a desire for diversification of platforms.
$0
$2,000
$4,000
$6,000
$8,000
$10,000
$12,000
$14,000
$16,000
$18,000
0
50
100
150
200
250
300
350
2015 2016 2017 2018 2019 YTD
Valu
e $M
# de
als
CNS Licensing Deals since 1/2015
number value
Discovery11%
Preclinical26%
Phase 18%
Phase 214%Phase 3
7%
Pre-Registration2%
Marketed32%
CNS Licensing Deals by Stage
Small Molecule63%
gene therapy8%
Antibody8%
Peptide6%
Protein5%
Cell Therapy5%
Oligo or Antisense
3%
RNAi1%
Enzyme1%
A Business Development Look at the CNS Landscape
19
LICENSING DEALS IN CNS SINCE JANUARY 2015
Biogen and Takeda have been the most active in-licensors in the last five years, but it’s notable that Biogen has only done about five deals a year. Therefore, if you’re looking for a partner, you might not be able to count on even a big dealmaker like Biogen.
CNS LICENSING DEALS BY COUNTRY AND TERRITORY
US companies are the most active in doing licensing deals in CNS.
0 5 10 15 20 25
Biogen Inc
Takeda Pharmaceutical Co Ltd
Janssen Pharmaceuticals Inc
Eisai Co Ltd
Pfizer Inc
AstraZeneca Plc
Grunenthal GmbH
Therapix Biosciences Ltd
Sanofi
Licensing Deals in CNS since 1/2015
0
20
40
60
80
100
120
140
160
United States United Kingdom Japan France Germany Canada
Num
ber o
f Dea
ls
CNS Licensing Deals by Country of HQ
2015 2016 2017 2018 2019
ShareVault and Pullan Consulting
20
0
100
200
300
400
500
600
US global Japan, notUK or US
UK, not US China, UKor US
Germany,not US
N America Europe
Deal Territories for CNS Licensing DealsSince 1/2015
US Global Japan(not withUK or US)
UK(not with
US)
China(not with UK or US)
Germany(not with
US)
N. America(notUS)
Europe(not UK
or Germany)
Licensing deals in CNS generally include the US even if they are not global. This is consistent with the US having the biggest sales in CNS drugs.
In summary, with tremendous unmet needs, large patient populations, CNS is a potentially exciting area.
But many diseases show pricing pressure of generics against the incremental improvements. With new approaches, new unserved diseases, the future is likely to be very different.
A Business Development Look at the CNS Landscape
21
About Linda Pullan, PhD Pullan Consulting
Linda and her team at Pullan Consulting offer biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a PhD in Biochemistry, a BS in Chemistry, and over twenty years of drug industry experience, including work on more than 75 deals.
About Pullan ConsultingSTRATEGY
Pullan Consulting can help you decide which studies will be more important for a partner or an investor. They can also help assess partnerability of new indications or programs.
OUTREACH
Pullan Consulting can mount an email partnering campaign, represent you at partnering meetings, and introduce you to investors. They have a very large database of industry contacts, along with notes on their interests, and they subscribe to databases to facilitate searches for companies in your space.
EVALUATIONS AND VALUATIONS
Pullan Consulting can assess differentiation from competition, both existing and in the pipeline. They can also model risk-adjusted discounted cash flow value of your drug candidate or of a deal.
NEGOTIATIONS
Pullan Consulting can help you prepare for a deal, both by considering the alternatives of deals and by evaluating your priorities. They can also lead negotiations for you or give advice on how to negotiate.
Pandesa Corporation, dba ShareVault
Headquarters 16795 Lark Avenue, Suite 210 Los Gatos, CA 95032
ShareVault is a registered trademark of Pandesa Corporation, dba ShareVault
Copyright © 2019 ShareVault. All rights reserved.
About ShareVault®
ShareVault offers secure, cloud-based document sharing solutions, also known as virtual data rooms, for organizations of all sizes looking to securely control and monitor highly confidential documents being shared with outside parties. Backed by the experience of billions of dollars in deal transactions, ShareVault’s solutions are used in due diligence for:
• Licensing and Partnering
• Fundraising and M&A
ShareVault is also used in other sensitive applications such as:
• CROs and CMOs sharing and protecting their SOPs
• Document sharing with consultants, vendors, distributors, Scientific Advisory Board and Board of Director members
• Document archiving for sponsor and regulatory audits
• University tech transfer licensing processes
ShareVault’s robust features together with its wide adoption and recognition in Life Sciences (44 out of the 45 largest pharma have used ShareVault) are just two of many reasons BIO and more than 50+ other regional associations have chosen ShareVault for their member savings programs. It is also why organizations in 48 countries have trusted ShareVault for their secure document sharing needs.
Toll-free USA 800.380.7652 | Worldwide 1.408.717.4955 sharevault.com